← Leaderboards
Oren Gilad
Atrin Pharmaceuticals
$815,523
Attributed
$2,296,569
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2016–24$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,296,569 · 2
By mechanism
R44$1,996,571 · 1
R41$299,998 · 1
Top collaborators
- Eric J Brown3 shared
- Fiona Simpkins2 shared
Others in their field
Top investigators on “Specificity”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Eric S Lander · Whitehead Institute For Biomedical Res$527,312,131
- Barton F Haynes · Duke University$483,626,898
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$395,980,920
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$381,706,339
Research focus
SpecificityChemotherapyHomologous RecombinationReportingTumorTumor XenograftDna Replication ForkGrowthOverexpressionPhosphotransferasesCombined Modality TherapyToxic EffectTumor GrowthBrca1 GeneBrca2 GeneDefectAttractin ProteinDoseCellsKinase InhibitorBiological AvailabilityPharmacologic SubstanceClinical DevelopmentClinical Trial Protocol
Grant awards (3)
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer$1,134,366
R44 · FY2024 · CA · contact PI
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer$862,205
R44 · FY2023 · CA · contact PI
Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers$299,998
R41 · FY2016 · CA